Hospital Director Lu Peihua was invited to participate in the 1st European CAR-T Cell Meeting

The 1st European CAR-T Cell Meeting was held in Paris, France on February 14-16, 2019. The meeting was organized by the European Association of Hematology (EHA) and the European Society for Blood and Bone Marrow Transplantation (EBMT). The scientists of the hematology and clinicians from all over the world come together to discuss the latest developments in the emerging CAR-T cell immunotherapy, share experiences and conduct collaborative research.
Lu Peihua, Director of Lu Daopei Hospital, was invited to attend the meeting as a guest speaker in the afternoon of February 15^th and gave a report ‘CAR-T Treatment for R/R B-CELL ALL: Experience from China .’

Director Lu Peihua said that up to now, Lu Daopei Hospital has completed more than 500 patients into the group to receive CAR-T therapy. As a single center, Lu Daopei Hospital has the largest number of CAR-T cases completed in China and the world, and accumulated a lot of experience. Clinical trials have shown that patients with refractory/relapsed acute B-lymphocytic leukemia who receive CAR-T have a higher response rate; cytokine release syndrome is controllable; many high-risk patients (such as high tumor burden, extramedullary invasion, PH-positive, TP53 mutations, and recurrence after allogeneic hematopoietic stem cell transplantation ) can also benefit from CAR-T;  central nervous system leukemia is not an absolute contraindication to CAR-T therapy; Overall survival and recurrence-free survival in patients with TP53 mutations were observed to be lower; patients who underwent CAR-T therapy re-bridged allogeneic hematopoietic stem cell had significantly better overall survival and recurrence-free survival than patient without bridge transplantation .

After attended the 60th Annual Meeting of American Hematology (ASH) in early December and the 2019 World Phacilitate Leaders Summit and World Stem Cell Summit (WSCS) in late January this year, Director Lu Peihua was once again invited to participate in an international academic meeting to share the results of the medical team in the CAR-T field. Lu Daopei's medical team's good efficacy and mature experience in CAR-T immunotherapy related research and clinical experimental data, CAR-T bridging transplantation and attracted extensive attention from hematologists around the world.
At the beginning of a new year, Director Lu Peihua and her leading medical team have received invitations from several international academic conferences. “Dao Pei Voice” will be sung in international academic forums. Lu Daopei Hospital will continue to strengthen its international peers and high-level experts. The sharing, exchange and cooperation will fully promote the innovation of blood disease treatment technology to improve the overall level of blood disease treatment and the development of the whole industry. Please pay attention to our follow-up reports.